New Era In Sterile Manufacturing: Recipharm and Exela Announce Exclusive Alliance

Recipharm, a leading contract development and manufacturing organization (CDMO), has entered into an exclusive strategic partnership with Exela Pharma Sciences, a US-based CDMO focused on client satisfaction. This alliance is set to enhance sterile manufacturing capabilities within the United States.

Through this collaboration, Recipharm will utilize Exela's advanced manufacturing facility in Lenoir, North Carolina. This facility, which is accredited by the FDA (CDER and CBER), boasts a successful history of executing projects at remarkable speeds, particularly during the COVID-19 pandemic. It specializes in the production of sterile injectable pharmaceuticals in both vial and pre-filled syringe (PFS) formats.

Greg Behar, CEO of Recipharm, said in a statement, "We are excited about this strategic alliance with Exela, which significantly enhances our manufacturing footprint in the US. This partnership aligns with our commitment to provide high-quality manufacturing solutions and expand our capabilities in the production of sterile products, such as GLP1, peptides, biologics, ADCs and other critical pharmaceuticals.”

“Recipharm is a highly respected CDMO with world-wide reach. We are honoured and excited to be Recipharm’s exclusive US partner. This collaboration offers a unique and efficient CDMO platform for biopharma customers that seek to participate in both US and EU markets and are looking for scale, speed and versatility with experience in delivering complex projects,” mentioned Phanesh Koneru, Ph.D., LL.M., president & CEO of Exela.